The Dividing Line for Germline Mutation Testing Is Often Arbitrary

Maurie Markman, MD
Published: Tuesday, Dec 17, 2019
Maurie Markman, MD, editor in chief, is president of Medicine and Science at Cancer Treatment Centers of America and clinical professor of medicine, Drexel University College of Medicine, Seattle Cancer Care Alliance

Maurie Markman, MD

It is difficult to overstate the impact on oncology practice of molecular evaluation of mutations and unique variants within the germline as well as the identification of somatic abnormalities within the cancer itself, such as specific mutations and recombination events.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication